Wellmarker Bio announced that two abstracts submitted to the American Cancer Society(AACR) annual meeting were selected for poster presentation. “Having the opportunity to present our candidates in the world’s largest cancer research conference has a great significance as it can be said that our drugs are recognized as promising drugs”, cited researcher from Wellmarker Bio.
Wellmarker Bio, a biotech startup developing first-in-class anti-cancer drugs based on predictive biomarker, is established in December 12, 2016. Details of the 2018 AACR abstracts are as follows.
Pipeline: WM-S1(Colon cancer treatment)
Title: Identification of a novel small-molecule inhibitor for treatment of human colon cancer patients
Pipeline: WM-A1(NSCLC treatment)
Title: Development of new mechanism based therapeutic antibodies in non-small cell lung cancer